Clinical Trial: Study of Imatinib, a Platelet-derived Growth Factor Receptor Inhibitor, and LBH589, a Histone Deacetylase Inhibitor, in the Treatment of Newly Diagnosed and Recurrent Chordoma

Study Status: Active, not recruiting
Recruit Status: Unknown status
Study Type: Interventional

Official Title: Multicenter Phase I Study of Imatinib, a Platelet-derived Growth Factor Receptor Inhibitor, and LBH589, a Histone Deacetylase Inhibitor, in the Treatment of Newly Diagnosed and Recurrent Same as current

Current Secondary Outcome:

• Tumor response [ Time Frame: Week 7 ]
  Tumor response will be evaluated using the RECIST criteria
• Tumor response [ Time Frame: Week 12 ]
  Tumor response will be evaluated using the RECIST criteria.

Original Secondary Outcome: Same as current

Information By: University of Virginia

Dates:
Date Received: July 28, 2010
Date Started: October 2011
Date Completion: December 2013
Last Updated: December 26, 2012
Last Verified: December 2012